4月10日，荣昌生物盘中上涨10.02%，截至13:20，报48.41元/股，成交3.71亿元，换手率4.97%，总市值263.51亿元。
资料显示，荣昌生物制药(烟台)股份有限公司位于中国山东省自由贸易试验区烟台片区烟台开发区北京中路58号，公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国均设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。
截至2月28日，荣昌生物股东户数6717，人均流通股5.23万股。
2024年1月-12月，荣昌生物实现营业收入17.17亿元，同比增长58.54%；归属净利润-14.68亿元，同比增长2.84%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.